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Abstract
When patients are told that standard medical treatment options have been exhausted, their treating physicians
may start looking for promising new drugs that are not yet approved, and still under investigation. Some patients
can be included in clinical trials, but others cannot. It is not widely known that these patients might still be eligible
for trying investigational drugs, in a therapeutic context. Worldwide, public and private parties are seeking to
change this by informing patients and physicians about opportunities for expanded access and/or by facilitating its
processes. When expanded access becomes available to larger groups of patients, ethical issues gain prominence,
including informed consent, funding issues, disparities in access, and potential adverse effects on clinical drug
development. Physicians, patients and policy-makers should not shift the responsibility to address these issues to
pharmaceutical companies, but work together to resolve them.
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Many countries have regulatory programs in place for ex-
panded access, also known as ‘compassionate use’ or
‘named-patient’ programs. Expanded access programs are
usually restricted to patients suffering from serious or life-
threatening diseases who have run out of standard
treatment options and cannot enroll in clinical trials, e.g.
because they do not meet the inclusion criteria. Requests
for expanded access are made by treating physicians and
evaluated by drug regulatory authorities. The pharmaceut-
ical company usually supplies the drug at no cost. In many
countries, the uptake of expanded access is low [1, 2]. This
is likely the result of both knowledge deficits and financial
issues. Firstly, physicians are not always aware of the pos-
sibility to prescribe drugs that are not yet approved for
marketing [3]. When they do, they may be held back by
unfamiliarity with the regulatory process, administrative
burdens, safety and/or liability concerns [4]. Patients and
patient organizations, likewise, seem to know little about
expanded access programs [5]. Secondly, in the absence of
any (economic) incentives to supply investigational drugs,
few companies are willing or able to provide expanded
access ‘out of compassion’.
Around the world, public and private initiatives are
currently trying to increase the availability of expanded
access beyond the highly selective group of patients who
are now able to use it. In the US in recent years, the
Right-to-Try movement has raised public awareness of
existing options for expanded access. Also, it has led to
the introduction of Right-to-Try legislation in over 30
American states, giving terminally ill patients the right
to use unapproved drugs directly, without approval from
the Food and Drug Administration (FDA). Despite broad
public and political support, Right-to-Try laws have been
criticized for offering no more than ‘false hope’ to
patients with unmet medical needs [6]. The laws do not
require pharmaceutical companies to release the
unapproved drugs, leaving patients without claim rights.
In effect, these laws seem to have led to little improve-
ment in making unapproved drugs more accessible for
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patients [6]. Some patients and patient advocacy groups
are using a different approach: Kids v. Cancer, for
example, has developed a ‘Compassionate Use Navigator’,
a clearinghouse of information about application pro-
cesses for expanded access, which also offers personal
assistance for the pediatric oncology community. A
similar initiative to inform patients can be found, for
instance, on the website of EURORDIS, an advocacy group
for rare diseases in Europe. Also, the FDA has significantly
improved its application process for expanded access to re-
duce the administrative burdens on physicians: it should
now take no more than 45 min to finalize a request [3].
Furthermore, commercial initiatives are stepping in to
increase accessibility of expanded access for patients. For
instance, the company myTomorrows has developed a
global online platform to inform patients and physicians
worldwide about local opportunities and regulations for
expanded access, and distributes a range of investigational
drugs through its own expanded access programs. Idis, a
contract research organization, runs so-called Managed
Access programs on behalf of pharmaceutical companies.
All these efforts – albeit different in many ways –
share one aim: to make expanded access a real option
for a much wider range of patients with unmet medical
needs, either through informing patients about expanded
access or by facilitating its processes. But, as a greater
uptake of unapproved drugs comes unlocked, ethical
issues associated with expanded access become more
pressing. For instance, the ethical requirement of in-
formed consent may be difficult to meet: physicians
must ensure that patients understand the ‘experimental’
nature of the treatment, the lack of complete safety and
efficacy data, and possible risks. Even properly informed
patients may still be biased by therapeutic misconcep-
tion [7]: an over-optimistic interpretation of potential
benefits and an underestimation of potential harms.
Some patients, however, will be well aware of their
limited chances at medical benefit, and nevertheless
willing to try. Furthermore, it is feared, expanded access
may thwart clinical trial enrolment, for patients will be
less willing to participate in randomized controlled trials
when they can access investigational drugs directly [8].
Thus, expanded access for individual patients runs coun-
ter to the goal of clinical drug development: the marketing
authorization of safe and effective drugs for the benefit of
entire patient populations. This concern, however, can be
addressed by the requirement that patients only qualify
for expanded access when they cannot be included in
clinical trials, which is already in place in many countries.
Most importantly, efforts to inform patients about ex-
panded access may be in vain as long as major obstacles
are not removed, including knowledge gaps among phy-
sicians. It is imperative that physicians are educated
about possibilities for expanded access and its regulatory
processes. Information and education may also help ad-
dress physicians’ liability concerns. In addition, solutions
should be sought for the general reluctance among
pharmaceutical companies to supply investigational
drugs outside the context of clinical trials. Commercial
initiatives like myTomorrows and Idis Managed Access
can assist companies with the expertise and infrastruc-
ture required for offering investigational drugs through
expanded access programs. Moreover, in some countries,
companies are allowed to charge, either freely or ‘direct
costs’ only [9] for unapproved drugs, which may
incentivize them to open up to expanded access. But the
problem of funding in expanded access runs deeper:
health insurers in many countries are commonly unwill-
ing to reimburse the costs of unapproved drugs.
Whereas some patients will be able to amass the
required sums, out of pocket or through fund-raising
campaigns [5], others will not, which gives rise to ethical
concerns related to equal access.
Some of these challenges can be overcome through the
development of consistent policies for expanded access.
As of yet, companies have not been transparent about the
conditions under which they will agree to provide ex-
panded access. The recently adopted 21st Century Cures
Act in the US requires that companies develop policies for
expanded access and make these policies publicly known
on their websites [10]. Other countries should follow suit,
for it is important that patients and physicians know what
to expect from expanded access. There is no consensus
yet, however, on what adequate policies for expanded ac-
cess look like, or which criteria should be used to deter-
mine whether or not patients are eligible for expanded
access. The responsibility to devise the contours of such
policies should not be shifted onto pharmaceutical com-
panies, but taken on by a variety of stakeholders, including
physicians, patients, policy-makers and payers. Together,
they must address the fundamental question whether or
not there is a place for expanded access in their healthcare
systems, and if yes, how this place should be set up to
allow for the responsible use of investigational drugs in
patients who have run out of standard treatment options
and cannot participate in clinical trials.
Conclusions
Efforts to facilitate expanded access will only give pa-
tients ‘false hope’ as long as current practical barriers
and ethical issues are not tackled. These include know-
ledge gaps, financial constraints, regulatory processes,
health disparities, and threats to clinical drug develop-
ment. Over the next few years, patients, physicians,
policy-makers and pharmaceutical companies must work
together to develop policies and systems to ensure equit-
able, safe and well-informed expanded access for pa-
tients with unmet medical needs.
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